Announcements

In its July 24, 2010 edition (click here for full article), THE WALL STREET JOURNAL reported that NPC disease has been selected as one of only three diseases initially selected for a new program at the National Institutes of Health called Therapeutics for Rare and Neglected Diseases or TRND.  Due to the initial success of …

DART and 4 other NPC family foundations continue their support of the SOAR-NPC collaborative effort.  SOAR-NPC is in essence a virtual biotech, pharmaceutical enterprise seeking a drug cocktail to arrest the progression of NPC.  In September 2009, at the National Institutes of Health, SOAR-NPC’s team was able to initiate its first human trial, and only …